The Business of Biofabrication

Auxilium Biotechnologies has bioprinted structures containing human kidney and liver cells aboard the International Space Station, marking what the company says is the first time either tissue type has been manufactured in space.

Using its AMP-1 orbital bioprinting platform, Auxilium produced kidney, liver, and cartilage tissues alongside 28 nerve-repair implants during the same mission. The materials returned to Earth aboard Mission AXLM-3 on NASA’s SpaceX CRS-34 flight, which splashed down off the California coast on June 17. The kidney and liver tissues were produced using cells and tissue designs supplied by the Wake Forest Institute for Regenerative Medicine.

The achievement is notable not because Auxilium printed replacement organs—it did not—but because one autonomous platform manufactured several biological products during a single mission. The printed structures are experimental tissue constructs rather than functioning kidneys or livers, and the returned samples are now being analyzed. Auxilium and its academic collaborators will still need to demonstrate cell viability, tissue function, structural consistency, and a meaningful advantage over comparable tissues produced on Earth.

Microgravity could address a specific manufacturing problem. On Earth, cells, drug particles, and other components can settle or become unevenly distributed within soft materials during fabrication. In microgravity, Auxilium believes it can exercise greater control over where those components are placed. More uniform cell distribution could eventually improve the quality of engineered tissues, organoids, or drug-eluting medical implants, although the company has not yet published comparative performance data showing that its orbital products outperform terrestrial equivalents.

Why it matters for biofabrication

The most important part of the mission may be the product mix. Space manufacturing is expensive, and a platform dedicated to one experiment or one low-volume product may struggle to justify launch and operating costs. A system that can manufacture tissue models, implants, and other biomedical products during the same flight has a more credible path toward spreading those costs across multiple customers and applications.

That makes AMP-1 less like a single scientific instrument and more like a small orbital manufacturing line. Auxilium is already positioning the platform for the commercial space-station era through collaborations with Vast and Starlab, which are developing potential successors to the ISS.

The business read

This mission demonstrates technical versatility, not yet commercial viability. The next questions are whether Auxilium can reproduce the results across missions, document better product quality, establish post-flight quality-control standards, and develop a regulatory path for materials manufactured partly or entirely in orbit.

The near-term opportunity may be more practical than printing complete organs. High-value tissue patches, organoids, drug-screening models, and specialized implants require less manufacturing volume and could better absorb the cost of orbital production. If Auxilium can show that microgravity creates a product that cannot be manufactured as effectively on Earth, spaceflight becomes part of the manufacturing process rather than an expensive setting for a scientific demonstration.

Sources: Auxilium Biotechnologies/Business Wire, July 9, 2026; Reuters, July 9, 2026.